(Q38010582)

26 August 2017

The application and mechanism of action of ribavirin in therapy of hepatitis C. (English)

1 reference

26 August 2017

1 reference

Emmanuel Thomas

1

1 reference

PubMed ID

22592135

26 August 2017

Marc G Ghany

series ordinal

2

1 reference

PubMed ID

22592135

26 August 2017

T Jake Liang

series ordinal

3

1 reference

26 August 2017

25 September 2012

1 reference

Antiviral Chemistry & Chemotherapy

26 August 2017

1 reference

26 August 2017

23

1 reference

26 August 2017

1

1 reference

26 August 2017

1-12

1 reference

Induction pegylated interferon alfa-2a and high dose ribavirin do not increase SVR in heavy patients with HCV genotype 1 and high viral loads

26 August 2017

1 reference

12 December 2020

Second-wave protease inhibitors: choosing an heir

1 reference

12 December 2020

An orally available, small-molecule interferon inhibits viral replication

1 reference

12 December 2020

Characterization of ribavirin uptake systems in human hepatocytes

1 reference

12 December 2020

Ribavirin regulates hepatitis C virus replication through enhancing interferon-stimulated genes and interleukin 8.

1 reference

12 December 2020

Plasma ribavirin concentrations during treatment of recurrent hepatitis C with peginterferon alpha-2b and ribavirin combination after liver transplantation

1 reference

12 December 2020

Ribavirin up-regulates the activity of double-stranded RNA-activated protein kinase and enhances the action of interferon-alpha against hepatitis C virus

1 reference

12 December 2020

Modelling how ribavirin improves interferon response rates in hepatitis C virus infection

1 reference

12 December 2020

Mechanism of action of interferon and ribavirin in treatment of hepatitis C

1 reference

12 December 2020

Treatment of chronic non-A,non-B hepatitis with recombinant human alpha interferon. A preliminary report

1 reference

12 December 2020

Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir

1 reference

12 December 2020

A pilot study of ribavirin therapy for chronic hepatitis C

1 reference

12 December 2020

The potentiating effect of ribavirin on interferon in the treatment of hepatitis C: lack of evidence for ribavirin-induced viral mutagenesis.

1 reference

12 December 2020

The effect of ribavirin and IMPDH inhibitors on hepatitis C virus subgenomic replicon RNA.

1 reference

12 December 2020

Inhibitors of IMP dehydrogenase prevent sindbis virus replication and reduce GTP levels in Aedes albopictus cells

1 reference

12 December 2020

Population pharmacokinetic and pharmacodynamic analysis of ribavirin in patients with chronic hepatitis C.

1 reference

12 December 2020

The role of ribavirin in direct acting antiviral drug regimens for chronic hepatitis C.

1 reference

12 December 2020

Ribavirin improves early responses to peginterferon through improved interferon signaling

1 reference

12 December 2020

Plasma/erythrocyte ribavirin x100 ratio as an indicator of sustained virological response in HCV genotype 1 patients with early virological response

1 reference

12 December 2020

Metabolism and antiviral activity of ribavirin

1 reference

12 December 2020

The clinical pharmacology of ribavirin

1 reference

12 December 2020

Initial Binding of the Broad Spectrum Antiviral Nucleoside Ribavirin to the Hepatitis C Virus RNA Polymerase

1 reference

12 December 2020

Molecular Mechanism of Hepatitis C Virus Replicon Variants with Reduced Susceptibility to a Benzofuran Inhibitor, HCV-796

1 reference

12 December 2020

Inosine triphosphate protects against ribavirin-induced adenosine triphosphate loss by adenylosuccinate synthase function

1 reference

12 December 2020

Ribavirin enhances interferon signaling via stimulation of mTOR and p53 activities

1 reference

12 December 2020

A cell-based, high-throughput screen for small molecule regulators of hepatitis C virus replication

1 reference

12 December 2020

Role of ribavirin in HCV treatment response: now and in the future

1 reference

12 December 2020

Ribavirin-induced anemia: mechanisms, risk factors and related targets for future research.

1 reference

12 December 2020

Impact of erythropoietin on sustained virological response to peginterferon and ribavirin therapy for HCV infection: a systematic review and meta-analysis.

1 reference

12 December 2020

Critical review of the use of erythropoietin in the treatment of anaemia during therapy for chronic hepatitis C.

1 reference

12 December 2020

ITPA gene variants protect against anaemia in patients treated for chronic hepatitis C.

1 reference

12 December 2020

Mutagenic and inhibitory effects of ribavirin on hepatitis C virus RNA polymerase

1 reference

12 December 2020

Peginterferon-alfa2a plus ribavirin for 48 versus 72 weeks in patients with detectable hepatitis C virus RNA at week 4 of treatment.

1 reference

12 December 2020

Pharmacokinetics and absolute bioavailability of ribavirin in healthy volunteers as determined by stable-isotope methodology.

1 reference

12 December 2020

Evolving epidemiology of hepatitis C virus

1 reference

12 December 2020

The role of ribavirin in the combination therapy of hepatitis C virus infection.

1 reference

12 December 2020

Efficacy of the protease inhibitor BI 201335, polymerase inhibitor BI 207127, and ribavirin in patients with chronic HCV infection

1 reference

12 December 2020

Role of nucleoside transporters SLC28A2/3 and SLC29A1/2 genetics in ribavirin therapy: protection against anemia in patients with chronic hepatitis C.

1 reference

12 December 2020

Management of hepatitis C in patients with chronic kidney disease

1 reference

12 December 2020

Threshold for neutropenia in the adjustment of interferon treatment in HCV infection

1 reference

12 December 2020

Ribavirin uptake by cultured human choriocarcinoma (BeWo) cells and Xenopus laevis oocytes expressing recombinant plasma membrane human nucleoside transporters

1 reference

12 December 2020

Dosage of ribavirin in patients with hepatitis C should be based on renal function: a population pharmacokinetic analysis.

1 reference

12 December 2020

Telaprevir and peginterferon with or without ribavirin for chronic HCV infection

1 reference

12 December 2020

Broad-spectrum antiviral activity of the IMP dehydrogenase inhibitor VX-497: a comparison with ribavirin and demonstration of antiviral additivity with alpha interferon

1 reference

12 December 2020

Hepatitis C virus RNA-dependent RNA polymerase (NS5B) as a mediator of the antiviral activity of ribavirin

1 reference

12 December 2020

The protease inhibitor, GS-9256, and non-nucleoside polymerase inhibitor tegobuvir alone, with ribavirin, or pegylated interferon plus ribavirin in hepatitis C.

1 reference

12 December 2020

Antiviral action of ribavirin in chronic hepatitis C.

1 reference

12 December 2020

The metabolism, pharmacokinetics and mechanisms of antiviral activity of ribavirin against hepatitis C virus

1 reference

12 December 2020

Molecular basis for the immunostimulatory activity of guanine nucleoside analogs: Activation of Toll-like receptor 7

1 reference

12 December 2020

Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection

1 reference

12 December 2020

Ribavirin monotherapy for chronic hepatitis C infection: a Cochrane Hepato-Biliary Group systematic review and meta-analysis of randomized trials

1 reference

12 December 2020

Mutation rate of the hepatitis C virus NS5B in patients undergoing treatment with ribavirin monotherapy

1 reference

12 December 2020

Antiviral effect and virus-host interactions in response to alpha interferon, gamma interferon, poly(i)-poly(c), tumor necrosis factor alpha, and ribavirin in hepatitis C virus subgenomic replicons

1 reference

12 December 2020

Aging of hepatitis C virus (HCV)-infected persons in the United States: a multiple cohort model of HCV prevalence and disease progression

1 reference

12 December 2020

Molecular analysis of the inhibitory effect of phosphorylated ribavirin on the vesicular stomatitis virus in vitro polymerase reaction

1 reference

12 December 2020

Preliminary study of two antiviral agents for hepatitis C genotype 1.

1 reference

12 December 2020

The next step for taribavirin

1 reference

12 December 2020

Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group

1 reference

12 December 2020

Boceprevir for untreated chronic HCV genotype 1 infection

1 reference

12 December 2020

Effects of antiviral therapy on the cellular immune response in acute hepatitis C.

1 reference

12 December 2020

Nucleoside transporters: from scavengers to novel therapeutic targets

1 reference

12 December 2020

Variants in the ITPA gene protect against ribavirin-induced hemolytic anemia and decrease the need for ribavirin dose reduction

1 reference

12 December 2020

Characterization of resistance to the protease inhibitor boceprevir in hepatitis C virus-infected patients

1 reference

12 December 2020

Maintenance therapy with ribavirin in patients with chronic hepatitis C who fail to respond to combination therapy with interferon alfa and ribavirin

1 reference

12 December 2020

Broad-spectrum antiviral activity of Virazole: 1-beta-D-ribofuranosyl-1,2,4-triazole-3-carboxamide

1 reference

12 December 2020

The antiviral compound ribavirin modulates the T helper (Th) 1/Th2 subset balance in hepatitis B and C virus-specific immune responses

1 reference

12 December 2020

Plasma disappearance, urine excretion, and tissue distribution of ribavirin in rats and rhesus monkeys

1 reference

12 December 2020

Update on alisporivir in treatment of viral hepatitis C.

1 reference

12 December 2020

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

1 reference

12 December 2020

Serum concentrations of ribavirin and pegylated interferon and viral responses in patients infected with HIV and HCV.

1 reference

12 December 2020

The Ribavirin Pregnancy Registry: Findings after 5 years of enrollment, 2003-2009.

1 reference

12 December 2020

Ribavirin treatment up-regulates antiviral gene expression via the interferon-stimulated response element in respiratory syncytial virus-infected epithelial cells

1 reference

12 December 2020

Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (I

1 reference

12 December 2020

Ribavirin Quantification in Combination Treatment of Chronic Hepatitis C

1 reference

12 December 2020

Strategies for managing anemia in hepatitis C patients undergoing antiviral therapy

1 reference

12 December 2020

Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection

1 reference

12 December 2020

Ribavirin resistance in hepatitis C virus replicon-containing cell lines conferred by changes in the cell line or mutations in the replicon RNA.

1 reference

12 December 2020

Structural effects on the phosphorylation of 3-substituted 1-beta-D-ribofuranosyl-1,2,4-triazoles by human adenosine kinase.

1 reference

12 December 2020

Impact of reducing peginterferon alfa-2a and ribavirin dose during retreatment in patients with chronic hepatitis C.

1 reference

12 December 2020

HCV natural history: the retrospective and prospective in perspective

1 reference

12 December 2020

Safety and efficacy of viramidine versus ribavirin in ViSER2: randomized, double-blind study in therapy-naive hepatitis C patients.

1 reference

12 December 2020

Potent immune activation in chronic hepatitis C patients upon administration of an oral inducer of endogenous interferons that acts via Toll-like receptor 7

1 reference

12 December 2020

Ribavirin treatment for chronic hepatitis C

1 reference

12 December 2020

Cyclophilin inhibitors: a novel class of promising host-targeting anti-HCV agents

1 reference

12 December 2020

The broad-spectrum antiviral ribonucleoside ribavirin is an RNA virus mutagen

1 reference

12 December 2020

High-dose ribavirin in combination with standard dose peginterferon for treatment of patients with chronic hepatitis C.

1 reference

12 December 2020

Significance of serum ribavirin concentration in combination therapy of interferon and ribavirin for chronic hepatitis C.

1 reference

12 December 2020

A randomized, double-blind, placebo-controlled dose-escalation trial of merimepodib (VX-497) and interferon-alpha in previously untreated patients with chronic hepatitis C.

1 reference

12 December 2020

Hepatitis C: current options for nonresponders to peginterferon and ribavirin.

1 reference

12 December 2020

S-adenosyl methionine improves early viral responses and interferon-stimulated gene induction in hepatitis C nonresponders

1 reference

12 December 2020

Quasispecies and its impact on viral hepatitis

1 reference

12 December 2020

Mutagenic effect of ribavirin on hepatitis C nonstructural 5B quasispecies in vitro and during antiviral therapy

1 reference

12 December 2020

Adenosine kinase initiates the major route of ribavirin activation in a cultured human cell line

1 reference

12 December 2020

The metabolism of ribavirin in erythrocytes and nucleated cells

1 reference

12 December 2020

Identification of a ribavirin-resistant NS5B mutation of hepatitis C virus during ribavirin monotherapy

1 reference

12 December 2020

Pharmacokinetics of ribavirin and urinary excretion of the major metabolite 1,2,4-triazole-3-carboxamide in normal volunteers.

1 reference

12 December 2020

Boceprevir for previously treated chronic HCV genotype 1 infection

1 reference

12 December 2020

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection

1 reference

12 December 2020

Recombinant interferon alfa therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial

1 reference

12 December 2020

Influence of a single nucleotide polymorphism at the main ribavirin transporter gene on the rapid virological response to pegylated interferon-ribavirin therapy in patients with chronic hepatitis C virus infection

1 reference

12 December 2020

Ribavirin aerosol treatment of serious respiratory syncytial virus infection in infants

1 reference

12 December 2020

Ribavirin treatment of experimental respiratory syncytial viral infection. A controlled double-blind study in young adults

1 reference

12 December 2020

Determination of ribavirin in serum using highly selective solid-phase extraction and high-performance liquid chromatography.

1 reference

12 December 2020

Interferons at age 50: past, current and future impact on biomedicine

1 reference

12 December 2020

Possible molecular mechanism of the relationship between NS5B polymorphisms and early clearance of hepatitis C virus during interferon plus ribavirin treatment

1 reference

12 December 2020

Ribavirin potentiates interferon action by augmenting interferon-stimulated gene induction in hepatitis C virus cell culture models

1 reference

12 December 2020

RNA virus error catastrophe: direct molecular test by using ribavirin

1 reference

12 December 2020

Mechanism of action of 1- -D-ribofuranosyl-1,2,4-triazole-3-carboxamide (Virazole), a new broad-spectrum antiviral agent

1 reference

12 December 2020

Intravenous ribavirin by constant infusion for serious influenza and parainfluenzavirus infection.

1 reference

12 December 2020

Immunology of hepatitis B virus and hepatitis C virus infection

1 reference

12 December 2020

The effect of interferon alfa and ribavirin combination therapy in naive patients with chronic hepatitis C.

1 reference

12 December 2020

Seminal fluid ribavirin level and functional semen parameters in patients with chronic hepatitis C on antiviral combination therapy

1 reference

12 December 2020

Ribavirin polarizes human T cell responses towards a Type 1 cytokine profile.

1 reference

12 December 2020

Nucleoside and non-nucleoside IMP dehydrogenase inhibitors as antitumor and antiviral agents

1 reference

12 December 2020

Hepatic gene expression during treatment with peginterferon and ribavirin: Identifying molecular pathways for treatment response

1 reference

12 December 2020

Treatment of chronic hepatitis C--are interferons really necessary?

1 reference

12 December 2020

Mammalian nucleoside transporters

1 reference

12 December 2020

Negative regulation of interferon-β gene expression during acute and persistent virus infections

1 reference

12 December 2020

Ribavirin inhibits viral-induced macrophage production of TNF, IL-1, the procoagulant fgl2 prothrombinase and preserves Th1 cytokine production but inhibits Th2 cytokine response.

1 reference

12 December 2020

Lassa fever. Effective therapy with ribavirin

1 reference

12 December 2020

Rapid viral response of once-daily TMC435 plus pegylated interferon/ribavirin in hepatitis C genotype-1 patients: a randomized trial

1 reference

12 December 2020

Treatment of hepatitis C virus genotype 2 and 3 with pegylated interferon plus ribavirin

1 reference

12 December 2020

Selection of hepatitis C virus resistant to ribavirin

1 reference

12 December 2020

Identifiers

DOI

10.3851/IMP2125

1 reference

26 August 2017

0 references

1 reference

PubMed ID

22592135